Our Products

We have ongoing programmes to bring our own gene silencing medicines to the clinic. We are actively seeking partners to accelerate these exciting products

Our gene silencing pipeline

Image
Image

A chemotherapy enhancer

This is our most advanced in-house product and originated from a collaboration withthe Medical Research Council in the UK. This unique siRNA payload downregulates the ITCH ubiquitin ligase in cancer cells, which allows the pro-apoptotic protein p73 to accumulate and sensitises the cancer to chemotherapy and radiotherapy. The Phase I trial in 2021 will focus on five solid tumour types.

To see how this drug could revitalise your chemotherapy portfolio click on the link below. 

Image

A novel glaucoma therapy

Trabeculectomy is a key surgical procedure used to treat glaucoma. But without antifibrotic therapy, the failure rate can be up to 74%. Even with the use of5-fluorouracil, failure rates are around 50% after five years. New, safe, non-toxic and efficacious treatments are urgently required so that the benefits of trabeculectomies are not just temporary. ECP-105 is a promising solution – just a single administration increased bleb survival and decreased scarring in vivo.